AdaptHealth to acquire Patient Care Solutions from McKesson
AdaptHealth, a US home medical equipment provider (HME provider), has agreed to acquire the Patient Care Solutions business…
ImmersiveTouch launches ImmersiveView 3.0 VR imaging platform for radiology
ImmersiveTouch, a US medical technology company, has introduced a new virtual reality imaging platform (VR imaging platform) called…
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been…
Global Blood Therapeutics bags Oxbryta FDA approval for sickle cell disease
Oxbryta FDA approval : Global Blood Therapeutics (GBT), a California-based biopharma company, has bagged approval for Oxbryta (voxelotor)…
Gsport creates cohesive bandages for human and animal patients
Gsport, a Chinese sports medicine company claims to have created high-quality cohesive bandages for human and animal patients.…
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to…
Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire…
Usona Institute gets FDA breakthrough status for psilocybin in MDD
Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration…
ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to…
ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase 3 ALTA-1L trial. The Japanese pharma company released updated data from the late-stage trial involving adult patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who did […]